Ginsenoside Rg1 attenuates invasion and migration by inhibiting transforming growth factor-β1-induced epithelial to mesenchymal transition in HepG2 cells

Molecular Medicine Reports

Volumn 11, Issue 4, 2015, Pages 3167-3173

  Yu, Meiling ^a   Yu, Xiaobing ^b   Guo, Daohua ^a   Yu, Binbin ^a   Li, Li ^b   Liao, Qiao ^a   Xing, Rong ^a  

^a BENGBU MEDICAL COLLEGE   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Epithelial to mesenchymal transition; Ginsenoside Rg1; Invasion; Migration; Transforming growth factor 1

Indexed keywords

BETA ACTIN; GINSENOSIDE RG 1; TRANSFORMING GROWTH FACTOR BETA1; UVOMORULIN; VIMENTIN; GINSENOSIDE; HERBACEOUS AGENT;

ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; EPITHELIAL MESENCHYMAL TRANSITION; HEPG2 CELL LINE; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; TUMOR INVASION; WESTERN BLOTTING; CELL MOTION; DRUG EFFECTS; GENE EXPRESSION; GENETICS;

PANAX GINSENG;

CELL MOVEMENT; DRUGS, CHINESE HERBAL; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION; GINSENOSIDES; HEP G2 CELLS; HUMANS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84921415103     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.3098     Document Type: Article

References (27)

1. Jemal A, Murray T, Ward E, et al: Cancer statistics, 2005. CA Cancer J Clin 55: 10-30, 2005.
2. Chaffer CL and Weinberg RA: A perspective on cancer cell metastasis. Science 331: 1559-1564, 2011.
3. Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell 144: 646-674, 2011.
4. Chang CJ, Chao CH, Xia W, et al: P53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol 13: 317-323, 2011.
5. Thiery J P, Acloque H, Huang RY, et al: Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890, 2009.
6. Voulgari A and Pintzas A: Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta 1796: 75-90, 2009.
7. Lee JM, Dedhar S, Kalluri R, et al: The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 172: 973-981, 2006.
8. Zavadil J and Böttinger EP: TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 24: 5764-5774, 2005.
9. Yang J and Weinberg RA: Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 14: 818-829, 2008.
10. Attele AS, Wu JA and Yuan CS: Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol 58: 1685-1693, 1999.
11. Lee EJ, Ko E, Lee J, et al: Ginsenoside Rg1 enhances CD4(+) T-cell activities and modulates Th1/Th2 differentiation. Int Immunopharmacol 4: 235-244, 2004.
12. Li CY, Deng W, Liao XQ, et al: The effects and mechanism of ginsenoside Rg1 on myocardial remodeling in an animal model of chronic thromboembolic pulmonary hypertension. Eur J Med Res 18: 16, 2013.
13. Li QF, Shi SL, Liu QR, et al: Anticancer effects of ginsenoside Rg1, cinnamic acid, and tanshinone IIA in osteosarcoma MG-63 cells: nuclear matrix downregulation and cytoplasmic trafficking of nucleophosmin. Int J Biochem Cell Biol 40: 1918-1929, 2008.
14. Liu J, Cai SZ, Zhou Y, et al: Senescence as a consequence of ginsenoside rg1 response on k562 human leukemia cell line. Asian Pac J Cancer Prev 13: 6191-6196, 2012.
15. Liu Q, Kou JP and Yu BY: Ginsenoside Rg1 protects against hydrogen peroxide-induced cell death in PC12 cells via inhibiting NF-κB activation. Neurochem Int 58: 119-125, 2011.
16. Qu DF, Yu HJ, Liu Z, et al: Ginsenoside Rg1 enhances immune response induced by recombinant Toxoplasma gondii SAG1 antigen. Vet Parasitol 179: 28-34, 2011.
17. Xu L, Chen WF and Wong MS: Ginsenoside Rg1 protects dopaminergic neurons in a rat model of Parkinson's disease through the IGF-I receptor signalling pathway. Br J Pharmacol 158: 738-748, 2009.
18. Li L, Wang Y, Qi B, et al: Suppression of PMA-induced tumor cell invasion and migration by ginsenoside Rg1 via the inhibition of NF-κB-dependent MMP-9 expression. Oncol Rep 32: 1779-1786, 2014.
19. Ellenrieder V, Hendler SF, Boeck W, et al: Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res 61: 4222-4228, 2001.
20. Chen J, Li Q, An Y, et al: CEACAM6 induces epithelial-mesenchymal transition and mediates invasion and metastasis in pancreatic cancer. Int J Oncol 43: 877-885, 2013.
21. Creighton CJ, Gibbons DL and Kurie JM: The role of epithelial-mesenchymal transition programming in invasion and metastasis: a clinical perspective. Cancer Manag Res 5: 187-195, 2013.
22. Polyak K and Weinberg RA: Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9: 265-273, 2009.
23. Thiery JP and Sleeman JP: Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7: 131-142, 2006.
24. Nagai T, Arao T, Furuta K, et al: Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma. Mol Cancer Ther 10: 169-177, 2011.
25. Shin JA, Hong OK, Lee HJ, et al: Transforming growth factor-β induces epithelial to mesenchymal transition and suppresses the proliferation and transdifferentiation of cultured human pancreatic duct cells. J Cell Biochem 112: 179-188, 2011.
26. Yang JJ, Lim JY, Huang J, et al: The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer. Clin Pharmacol Ther 94: 252-259, 2013.
27. Li J, Wei Q, Zuo GW, et al: Ginsenoside Rg1 induces apoptosis through inhibition of the EpoR-mediated JAK2/STAT5 signalling pathway in the TF-1/Epo human leukemia cell line. Asian Pac J Cancer Prev 15: 2453-9, 2014.